Navigation Links
CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
Date:10/17/2008

RESEARCH TRIANGLE PARK, N.C., Oct. 17 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today announced that it has initiated a Phase II clinical trial for its lead product candidate Tyrima(TM) for the treatment of major depressive disorder (MDD). Tyrima is a selective and reversible member of a novel class of drugs known as RIMAs, or reversible inhibitors of monoamine oxidase A (MAO-A). The primary objective of this Phase II trial is to evaluate the antidepressant efficacy of Tyrima in patients with confirmed MDD. The trial design incorporates a number of features intended to reduce the variability and placebo response often observed in MDD clinical trials.

The randomized, double-blind, placebo-controlled Phase II trial will enroll approximately 272 patients with moderate to severe MDD who will receive either Tyrima or placebo for six weeks. The primary study objective of antidepressant efficacy will be assessed using the Montgomery-Asberg Depression Rating Scale (MADRS). Secondary objectives of the study include evaluation of safety, tolerability, and pharmacokinetics of Tyrima. The trial design was supported by a Tyrima Phase I safety database of 106 subjects and a PET (positron emission tomography) study that yielded critical insight into the dose-response relationship of Tyrima. A number of patients are already randomized in the trial and initial results are expected by the end of 2009.

"Tyrima has the potential to be the first triple-action antidepressant with a safety profile appropriate for the treatment of a broad population of patients with depression, and we are committed to generating robust clinical data from this Phase Il trial," said Dr. Daniel Burch, Executive Vice President of R&D and Chief Medical Officer of CeNeRx. "We worked closely with experienced MDD clinical trial experts, disease specialists, and biostatisticia
'/>"/>

SOURCE CeNeRx BioPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
2. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
3. InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
4. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
5. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
6. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
7. Canopus BioPharma Strengthens its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement With Wisconsin Alumni Research Foundation
8. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
9. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
10. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
11. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... --  Hospira, Inc. (NYSE: HSP ), ... leading provider of injectable drugs and infusion technologies, ... biosimilarity of its proposed biosimilar, Epoetin Hospira, with ... approved name of RETACRIT™, compared to the reference ... were presented at the National Kidney Foundation (NKF) ...
(Date:3/27/2015)... , March 27, 2015  Delcath Systems, ... and medical device company focused on oncology with ... metastatic liver cancers, announces the reporting of data ... Melphalan Hydrochloride for Injection with the Delcath Hepatic ... poster presentation at the Society of Surgical Oncology ...
(Date:3/26/2015)... 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or ... on Omega-3 therapies for cardiovascular disease and overall health, ... common shares of the Corporation (the "Common Shares"). The ... of December 5 th , 2014 to March 4 ... is due on or before April 1, 2015. Interest ...
Breaking Medicine Technology:Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2
(Date:3/27/2015)... 27, 2015 Operatic contenders and their ... on April 17th. The universally acclaimed baritone Sherrill Milnes ... annual Opera Idol at The Merion in Evanston. The ... has drawn aspiring opera singers from around the country. ... of the finest young talent in the country,” said ...
(Date:3/27/2015)... MN (PRWEB) March 27, 2015 ... Minnesotans for Healthy Kids Coalition Lobby Day to ... Statewide Health Improvement Program (SHIP). Everlast Climbing ... 2015 PE Bill SF343/HF498 which would strengthen physical ... annual student assessments and other measures to strengthen ...
(Date:3/27/2015)... Jersey (PRWEB) March 27, 2015 Airy ... has released the official music video for her debut ... , Combining live-action and abstract styling effects, the ... be viewed on YouTube, Vimeo, and assorted outlets. It ... the development of an expanding full-scale marketing strategy. The ...
(Date:3/27/2015)... April 2015 is the 150th anniversary of the ... America’s bloodiest war and the amazing President that led our ... to the Civil War and Abraham Lincoln. This moving event ... the Jane Pickens Theater in Newport, RI. , Chief ... as the master of ceremonies. Dr. Fred Zilian, educator, writer ...
(Date:3/27/2015)... 27, 2015 The Florida Center for ... Cancer Cure (ABC2), awarded $350,000 to support brain cancer ... The Scripps Research Institute and H. Lee Moffitt Cancer ... with a clear development path and potential to provide ... near future. , The awards fund research in ...
Breaking Medicine News(10 mins):Health News:Opera Idol Competition At The Merion In Evanston 2Health News:Everlast Climbing Advocates to Strengthen Physical Education in Minnesota Schools 2Health News:Airy Jeanine Releases ‘’Mama’s Girl” Official Music Video 2Health News:Relive the Civil War, the Presidency and Shocking Assassination of Abraham Lincoln through Lincoln’s Own Words and the Music of a 46-Piece Orchestra 2Health News:Relive the Civil War, the Presidency and Shocking Assassination of Abraham Lincoln through Lincoln’s Own Words and the Music of a 46-Piece Orchestra 3Health News:Relive the Civil War, the Presidency and Shocking Assassination of Abraham Lincoln through Lincoln’s Own Words and the Music of a 46-Piece Orchestra 4Health News:The Florida Center for Brain Tumor Research and Accelerate Brain Cancer Cure Award $350,000 to Florida-Based Researchers 2Health News:The Florida Center for Brain Tumor Research and Accelerate Brain Cancer Cure Award $350,000 to Florida-Based Researchers 3
... wellbeing and inclusion of former politically motivated prisoners in ... (Monday 14 March). Ageing and Social Exclusion ... the border region of Ireland investigated the well being ... former prisoners (aged 50 and over) as older people ...
... (March 14, 2011) Research has shown that playing a ... children, but playing a used instrument also can pose a ... instruments were found to be heavily contaminated with a variety ... minor to serious infectious and allergic diseases, according to a ...
... (HealthDay News) -- Watching this year,s NCAA March Madness basketball ... on the games, one expert suggests. Though the current ... boards seems to suggest that predicting the outcome of games ... Nowlis, a marketing professor at the Olin Business School at ...
... to resist the targeted drug Herceptin, but a single ... vulnerability to treatment, scientists at The University of Texas ... Nature Medicine . Adding the drug saracatinib to ... at least five different molecular pathways, each of which ...
... , FRIDAY, March 11 (HealthDay News) -- People would prefer ... especially if they know others are watching, says a new ... likely to think badly of them if they do something ... to the research in the journal Psychological Science . ...
... March 11 (HealthDay News) -- A doctor,s empathy can improve ... important part of being a good doctor, according to a ... between July 2006 and June 2009 by 29 doctors at ... doctors, level of empathy for patients, while the quality of ...
Cached Medicine News:Health News:Report into well-being and inclusion of former politically motivated prisoners 2Health News:Report into well-being and inclusion of former politically motivated prisoners 3Health News:Is your child's hobby making him sick? 2Health News:Combination overcomes breast cancer resistance to herceptin 2Health News:Combination overcomes breast cancer resistance to herceptin 3Health News:When Someone Is Watching, You're Less Inclined to Do Bad Things 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: